Takeda Pharmaceutical has revised its financial results for fiscal year 2025 following a significant legal development in the United States involving its constipation drug, Amitiza (lubiprostone).
The company announced that it has recorded an additional legal provision of approximately JPY 402.5 billion related to ongoing antitrust litigation in the U.S. The revision follows a recent jury verdict that found Takeda liable in a case alleging that generic competition for Amitiza was improperly delayed. As part of the financial adjustment, Takeda also recognized related tax benefits amounting to JPY 58.4 billion.
According to Takeda, the revised earnings report reflects the estimated financial impact of the litigation on its FY2025 consolidated financial statements. The company emphasized that the adjustment does not affect its core operating performance, indicating that its underlying business operations remain unchanged despite the legal charge.
The legal dispute centers on allegations that Takeda entered into agreements that delayed the launch of lower-cost generic versions of Amitiza. In May 2026, a U.S. jury awarded substantial damages to plaintiffs, including wholesalers and retailers, in the antitrust case. Takeda has stated that it disagrees with the verdict and intends to pursue post-trial motions and an appeal.
While the litigation has created a sizeable one-time financial impact, Takeda noted that it continues to focus on its long-term business strategy and patient-focused healthcare initiatives. The company is expected to provide further updates as legal proceedings continue.ac
